Akebia Announces Establishment of Rare Kidney Disease Pipeline
Akebia Announces Establishment of Rare Kidney Disease Pipeline GlobeNewswire December 01, 2025 Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both […]